FDA Panel Votes Against First-line Use For Luitpold’s Iron Deficiency Drug Injectafer
This article was originally published in The Pink Sheet Daily
Executive Summary
Concerned about off-label use of the drug in patients with critical kidney disease, advisory committee suggests that if approved, Injectafer label should include “very descriptive prescribing” instructions.